ArticleHealthcare policy = Politiques de sante2011
Access to cancer drugs in Canada: looking beyond coverage decisions.
Article in Healthcare policy = Politiques de sante, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?Healthcare policy = Politiques de sante · 2015Pooled it
- Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical Oncologists.Current oncology (Toronto, Ont.) · 2021Article
- Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada.Current oncology (Toronto, Ont.) · 2021Article
- Resident-Level Predictors of Dementia Pharmacotherapy at Long-Term Care Admission: The Impact of Different Drug Reimbursement Policies in Ontario and Saskatchewan: Prédicteurs de la pharmacothérapie de la démence au niveau des résidents lors de l'hospitalisation dans des soins de longue durée : l'impact de différentes politiques de remboursement des médicaments en Ontario et en Saskatchewan.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2020Article
- Inter- and intraprovincial inequities in public coverage of cancer drug programs across Canada: a plea for the establishment of a pan-Canadian pharmacare program.Current oncology (Toronto, Ont.) · 2019Article
- Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.BMC health services research · 2017Article
- The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation?The International journal of health planning and management · 2017Article
- Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?ClinicoEconomics and outcomes research : CEOR · 2017Review
- Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example.Journal of market access & health policy · 2016Article
- Overcoming obstacles in accessing unfunded oral chemotherapy: physician experience and challenges.Journal of oncology practice · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine variation in patients' access to a set of cancer drugs through publicly funded provincial drug programs. DATA SOURCES/STUDY
designWe surveyed provincial drug program managers about their highest-expenditure intravenous and oral cancer drugs. We then investigated whether the same cancer drugs account for the highest expenditures across the provincial programs. We also compared the rates at which these drugs are accessed through these programs. PRINCIPAL
findingsWhile there is moderate consistency in the selection of cancer drugs that account for the highest provincial expenditures, considerable differences were found in the rates at which some drugs are accessed across provincial programs.
conclusionsThe study demonstrates the existence of interprovincial variation in publicly funded access to cancer drugs even after these drugs have been approved for public coverage.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.